Skip to content

Study · Randomized controlled trial · n = 35 · 2018

8 results

Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss.

Simeone P, Liani R, Tripaldi R, Di Castelnuovo A, Guagnano MT, Tartaro A, Bonadonna RC, Federico V, Cipollone F, Consoli A, Santilli F

Nutrients2 Dec 2018Cited by 27 (Europe PMC)

PMID30513818 (opens in a new tab)PMCIDPMC6315606 (opens in a new tab)DOI10.3390/nu10121872 (opens in a new tab)PepBankPUB-30513818
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Thromboxane (TX)-dependent platelet activation and lipid peroxidation, as reflected in vivo by the urinary excretion of 11-dehydro-TXB₂ and 8-iso-prostaglandin (PG)F2α, play a key role in atherothrombosis in obesity and type 2 diabetes mellitus (T2DM) since the earlier stages. Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling until achieving a comparable weight loss (-7% of initial body weight), to assess whether changes in subcutaneous (SAT) and visceral (VAT) adipose tissue distribution (MRI), insulin sensitivity (Matsuda Index) and beta-cell performance (multiple sampling OGTT beta-index), with either intervention, might affect TX-dependent platelet activation, lipid peroxidation and inflammation. At baseline, Ln-8-iso-PGF2α (Beta = 0.31, p = 0.0088), glycosylated hemoglobin (HbA1c) (Beta = 2.64, p = 0.0011) Ln-TNF-α (Beta = 0.58, p = 0.0075) and SAT (Beta = 0.14, p = 0.044) were significant independent predictors of 11-dehydro-TXB₂. After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP). In obese patients with initial impairment of glucose metabolism, the extent of platelet activation is related to systemic inflammation, isoprostane formation and degree of glycemic control and abdominal SAT. Successful weight loss, achieved with either lifestyle changes or an incretin-based therapy, is associated with a significant reduction in lipid peroxidation and platelet activation.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In metformin-treated obese adults with prediabetes or early type 2 diabetes, urinary 11-dehydro-TXB2, a marker of platelet activation, fell after liraglutide-induced weight loss.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, a platelet activation marker fell after weight loss with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseUrinary 11-dehydro-TXB2 after weight loss, liraglutide arm
    Study

    n = 35

    Comparator
    Lifestyle counseling
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mg/day · until 7% weight lossAs given in this study (human).

    Source sentences

    Summary
    After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP).
    1 context sentence
    Summary · context
    Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or early type 2 diabetes, the fall in urinary 11-dehydro-TXB2 with liraglutide did not differ from lifestyle counseling at comparable weight loss.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, the platelet marker fell about the same with liraglutide as with lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    No significant changeUrinary 11-dehydro-TXB2 versus lifestyle
    Study

    n = 35

    Comparator
    Lifestyle counseling
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mg/day · until 7% weight lossAs given in this study (human).

    Measurements

    Between-group p
    0.679
    11-dehydro-TXB2

    Source sentences

    Summary
    After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP).
    1 context sentence
    Summary · context
    Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling
  3. 03HumanRandomized controlled trialEfficacy outcome

    In metformin-treated obese adults with prediabetes or early type 2 diabetes, urinary 8-iso-PGF2α, a lipid peroxidation marker, fell after liraglutide-induced weight loss.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, a marker of oxidative stress fell after weight loss with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseUrinary 8-iso-PGF2alpha after weight loss, liraglutide arm
    Study

    n = 35

    Comparator
    Lifestyle counseling
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    1.8 mg/day · until 7% weight lossAs given in this study (human).

    Source sentences

    Summary
    After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP).
    1 context sentence
    Summary · context
    Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or early type 2 diabetes, the fall in urinary 8-iso-PGF2α with liraglutide did not differ from lifestyle counseling at comparable weight loss.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, the oxidative stress marker fell about the same with liraglutide as with lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    No significant changeUrinary 8-iso-PGF2alpha versus lifestyle
    Study

    n = 35

    Comparator
    Lifestyle counseling
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    1.8 mg/day · until 7% weight lossAs given in this study (human).

    Measurements

    Between-group p
    0.985
    8-iso-PGF2alpha

    Source sentences

    Summary
    After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP).
    1 context sentence
    Summary · context
    Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling
  5. 05HumanRandomized controlled trialEfficacy outcome

    In metformin-treated obese adults with prediabetes or early type 2 diabetes, glycemic control improved with liraglutide-induced weight loss, comparably to the lifestyle arm.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, blood sugar control improved with liraglutide, about as much as with lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    Not applicableGlycemic control after weight loss
    Study

    n = 35

    Comparator
    Lifestyle counseling
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · until 7% weight lossAs given in this study (human).

    Source sentences

    Summary
    After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP).
    1 context sentence
    Summary · context
    Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling
  6. 06HumanRandomized controlled trialEfficacy outcome

    In metformin-treated obese adults with prediabetes or early type 2 diabetes, insulin sensitivity improved with liraglutide-induced weight loss, comparably to the lifestyle arm.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, insulin sensitivity improved with liraglutide, about as much as with lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin sensitivity after weight loss
    Study

    n = 35

    Comparator
    Lifestyle counseling
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · until 7% weight lossAs given in this study (human).

    Source sentences

    Summary
    After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP).
    1 context sentence
    Summary · context
    Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling
  7. 07HumanRandomized controlled trialEfficacy outcome

    In metformin-treated obese adults with prediabetes or early type 2 diabetes, subcutaneous adipose tissue improved with liraglutide-induced weight loss, comparably to the lifestyle arm.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, fat under the skin improved with liraglutide, about as much as with lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    DecreaseSubcutaneous adipose tissue after weight loss
    Study

    n = 35

    Comparator
    Lifestyle counseling
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/day · until 7% weight lossAs given in this study (human).

    Source sentences

    Summary
    After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP).
    1 context sentence
    Summary · context
    Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling
  8. 08HumanRandomized controlled trialEfficacy outcome

    In metformin-treated obese adults with prediabetes or early type 2 diabetes, hs-CRP improved with liraglutide-induced weight loss, comparably to the lifestyle arm.

    In plain wordsIn obese adults with prediabetes or early type 2 diabetes, an inflammation marker improved with liraglutide, about as much as with lifestyle changes.

    Peptide
    Liraglutide
    Outcome
    DecreaseHigh-sensitivity C-reactive protein after weight loss
    Study

    n = 35

    Comparator
    Lifestyle counseling
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    1.8 mg/day · until 7% weight lossAs given in this study (human).

    Source sentences

    Summary
    After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB₂ (between-group p = 0.679) and 8-iso-PGF-2α (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP).
    1 context sentence
    Summary · context
    Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.